Nutriband Inc. Appoints Two New Directors, Updates on AVERSA Fentanyl Development

Nutriband Inc. has provided an update on its annual shareholder meeting, held on January 24, 2026. The company discussed key milestones and additions, including the appointment of two new directors, Alessandro Puddu and Viorica Carlig. Nutriband also highlighted developments in its AVERSA™ FENTANYL project, including strengthened collaboration with Kindeva, completion of commercial manufacturing process scale-up, and issuance of a new US patent. The company held a Type C meeting with the US FDA to obtain feedback on its Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL.